Allogeneic stem cell transplantation for patients with metastatic renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 6, Issue 10, 2006, Pages 1449-1458

  Roigas, Jan ^a   Johannsen, Manfred ^a   Ringsdorf, Martin ^a   Massenkeil, Gero ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Allogeneic stem cell transplantation; Donor lymphocyte infusions; Metastatic renal cell carcinoma; Reduced intensity conditioning; Targeted theraphy

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYTOKINE; FLUOROURACIL; INTERLEUKIN 2; ISOTRETINOIN; MEDROXYPROGESTERONE ACETATE; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; VASCULOTROPIN ANTIBODY; VINBLASTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANGIOGENESIS; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DONOR; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; FOOD AND DRUG ADMINISTRATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LYMPHOCYTE TRANSFUSION; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NAUSEA; NEPHRECTOMY; PATIENT SELECTION; REDUCED INTENSITY CONDITIONING; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMATITIS; UNITED STATES;

CARCINOMA, RENAL CELL; GRAFT VS HOST DISEASE; HUMANS; KIDNEY NEOPLASMS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 33750690168     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.10.1449     Document Type: Review

References (60)

1. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J. Urol. 167, 57-60 (2002).
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin. 56, 106-130 (2006).
3. Bukowski RM, Negrier S, Elson P. Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin. Cancer Res. 10, 6310S-6314S (2004).
4. Mickisch GH, Garin A, van Poppel H et al. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358, 966-970 (2001).
5. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655-1659 (2001).
6. Flanigan RC, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171, 1071-1076 (2004).
7. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530-2540 (1999)
8. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 22, 454-463 (2004).
9. Steiner T, Roigas J, Kirchner H et al. Clinical course of patients with metastatic papillary renal cell carcinoma, 2006 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 24(18S), 14591 (2006).
10. Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353, 14-17 (1999).
11. Pyrhonen S, Salminen E, Ruucu M et al. Prospective randomized trial of interferon α-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. 17, 2859-2867 (1999).
12. Motzer RJ, Murphy BA, Bacik J et al. Phase III trial of interferon α-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J. Clin. Oncol. 18, 2972-2980 (2000).
13. Aass N, De Mulder PH, Mickisch GH et al. Randomized Phase II/III trial of interferon α-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J. Clin. Oncol. 23, 4172-4178 (2005)
14. Atzpodien J. Hoffmann R, Franzke M et al. Thirteen-year, long-term efficacy of interferon 2α, and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer 95, 1045-1050 (2002).
15. Fisher RI, Rosenberg SA, Eyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci, Am. 6(S1), 55-57 (2000).
16. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21, 3127-3132 (2003).
17. McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133-141 (2005).
18. Atzpodien J, Kirchner H, Illiger HJ et al. IL-2 in combination with IFN-α and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br. J. Cancer 85, 1130-1136 (2001).
19. Atzpodien J, Kirchner H, Jonas U et al. Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Interleukin-2- and interferon α-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J. Clin. Oncol. 22, 1188-1194 (2004).
20. Negrier S, Caty A, Lesimple T et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon α with or without fluorouracil. J. Clin, Oncol. 18, 4009-4015 (2000).
21. Negrier S, Perol D, Ravaud A et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 23(16S), 4511 (2005).
22. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. 25, CD001425 (2005).
23. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral- blood stem-cell transplantation. N. Engl. J. Med. 343, 750-758 (2000).
24. Weiden PL, Flournoy N, Thomas ED et L. antileukemioc effect of graft-versus-host disease in human recipients of allogeneic- marrow grafts. N. Engl. J. Med. 300, 1068-1073 (1979).
25. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75. 555-562 (1990).
26. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86, 2041-2050 (1995)
27. Goulmy E. Minor histocompatibility antigens: allo target molecules for tumor specific immunotherapy. Cancer J. 10, 1-7 (2004).
28. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94, 3234-3241 (1999).
29. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog- containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89, 4531-4536 (1997).
30. Slavin S, Nagler A, Naparstek E et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematological diseases. Blood 91, 756-763 (1998).
31. Mapara MY, Kim Y-M, Wang SP, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions (DLI) mediate superior graft-versus-leukemia (GVL) effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 100, 1903-1909 (2002).
32. Parker JE, Shafi T, Pagliuca A et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br. J. Haematol. 119. 144-154 (2002).
33. Dreger P, van Biezen A, Brand R et al. Reduced-intensity conditioning lowers treatment-related mortality (TRM) of allogeneic stem cell transplantation (SCT) for CLL: a retrospective study on 448 patients. Blood 102, 197A (2003).
34. Diaconescu R, Flowers CR, Storer B et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104, 1550-1558 (2004).
35. Eibl B, Schwaighofer H, Nachbaur D et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88. 1501-1508 (1996).
36. Ueno NT. Rondon G. Mirza NQ et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J. Clin. Oncol. 16. 986-993 (1998).
37. Bay JO, Fleury J, Choufi B et al. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant. 30, 95-102 (2002).
38. + selected tumor infiltrating lymphocytes from primary tumor. J. Urol. 158, 740-745 (1997).
39. Fairlamb DJ. Spontaneous regression of metastases of RCC: a report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature. Cancer 47, 2102-2106 (1981).
40. Figlin RA, Thompson JA, Bukowski RM et al. Multicenter, randomized, Phase III trial of CD8 tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J. Clin. Oncol. 17. 2521-2529 (1999).
41. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J. Clin. Oncol. 20, 2017- 2024 (2002).
42. Blaise D, Bay JO, Faucher C et al. Reduced- intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 103, 435-441 (2004).
43. Bregni M, Dodero A, Peccatori J et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99, 4231-4236 (2002).
44. Pedrazzoli F, Da Prada GA, Giorgiani G et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 94, 2409-2415 (2002).
45. Hentschke P, Barkholt L, Uzunel M et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant. 31, 253-261 (2003).
46. Ueno NT, Cheng YC, Rondon G et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102, 3829-3836 (2003).
47. Massenkeil G, Roigas J, Nagy M et al. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant. 34, 309-316 (2004).
48. Nakagawa T, Kami M, Hori A et al. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. Exp. Hematol. 32, 599-606 (2004).
49. Tykodi SS, Warren EH, Thompson JA et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin. Cancer Res. 10, 7799-7811 (2004).
50. Rzepecki P, Zolnierek J, Sarosiek T, Langiewicz P, Szczylik C. Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma - single center experience. Neoplasma 52, 238-242 (2005).
51. Barkholt L Bregm M, Remberger M et al. Allogeneic haematopoietic stem cell transplantation for renal carcinoma in Europe. Ann. Oncol. 17, 1134-1140 (2006).
52. Peccatori J, Barkholt L, Demirer T et al. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer 104, 2099-2103 (2005).
53. Artz AS, Kocherginsky M, Van Besien K. Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantation. Br. J. Haematol. 132, 747-754 (2006).
54. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97, 3390-3400 (2001).
55. Massenkeil G, Nagy M, Lawang M et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can he achieved. Bone Marrow Transplant. 31, 339-345 (2003).
56. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85-90 (1994).
57. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003).
58. Eisen T, Bukowski RM, Staehler M, et al. Randomized Phase III trial of Sorafenib in advanced renal cell carcinoma: impact of cross-over on survival. 2006 ASCO Annual Meeting Proceedings. J. Clin. Oncol 24(18S), 4524 (2006).
59. Motzer RJ, Hutson TE, Tomczak P et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-α (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). 2006 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 24(18S), LBA3 (2006).
60. Hudes G, Carducci M, Tomczak P et al. A Phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-α (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). 2006 ASCO Annual Meeting Proceedings. Clin. Oncol. 24 (18S), LBA4 (2006).